Annex

QUESTIONNAIRE FOR THE TESTING OF THE GUIDANCE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

GENERAL INFORMATION ABOUT THE TESTING							
Q1. These results are being submitted on behalf of a:	☐ Party. Please specify: Bolivia						
	☐ Other Government. Please specify: <country's name=""></country's>						
	☐ Organization: Please specify: <organization's name=""></organization's>						
Q2. When was the testing of the Guidance conducted?	Please enter date: November - December, 2011						
Q3. Type of event where the testing of the Guidance was conducted?	Group event (e.g., workshop, training course, meeting). Please provide the title of the event and name of organizer: <type here=""></type>						
	Type of meeting:						
	Online						
	Individual exercise. Please provide your name, occupation and affiliation: <type here=""></type>						
	Other: Please specify: Group revision by personnel of the Vice-Ministry of Environment						
	☐ Part I: The Roadmap for Risk assessment of LMOs						
	Part II: Specific types of LMOs or Traits:						
Q4. Which sections of the Guidance were tested?	☐ Risk assessment of LMOs with stacked genes or traits						
	Risk assessment of LM crops with tolerance to abiotic stress						
	☐ Risk as	ssessment of	LM mosquite	oes			
OVERALL EVALUATION							
		Very poor	Poor	Neutral	Good	Very good	
Please indicate the level of agreement you a	attribute to each of t	he questions	in the left col	umn.			
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?							
Q6. How do you evaluate the usefulness as a tool to assist countries in conducting an assessments of LMOs in a scientifically sou case manner?	d reviewing risk				\boxtimes		
Q7. How do you evaluate the usefulness as a tool to assist countries in conducting an assessments of LMOs introduced into variouenvironments?	d reviewing risk				\boxtimes		

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.					
Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>			
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes	Comments: Yes since it provides the fundamentals for risk assessment framework, however, it needs to be supported by specific technical guidance, which go beyond the scope of this guidance / Roadmap.			
Q10. Is the Roadmap organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>			
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>			
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	⊠ Yes □ No	Comments: However if has certain focus on crops VM due to the examples used.			
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes □ No	Comments: However it needs this specification in the introductory text, said that it would be useful to explicit that the Guidance / Roadmap applies to all types of introductions into the environment			
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ⊠ No	Comments: <type here=""></type>			
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: It is very useful, however it will be enriched if "Related issues" are spell out in the flowchart.			

PART II: SPECIFIC TYPES OF LIVING MODIFIED ORGANISMS OR TRAITS

Risk assessment of living modified organisms with stacked genes or traits

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q16. Does this section provide useful guidance when conducting risk assessments of LMOs with stacked genes or traits in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q17. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LMOs with stacked genes of traits?	⊠ Yes	Comments: Idem as comment to Q9				
Q18. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q19. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes	Comments: <type here=""></type>				
Q20. Is there any other issue or concept that you would like to see included in this section of the Guidance?	⊠ Yes	Comments: Key guiding questions or a check list				
Risk assessment of living modified crops with tolerance to abiotic stress						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q21. Does this section provide useful guidance when conducting risk assessments of LM crops with tolerance to abiotic stress(es) in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q22. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM crops with tolerance to abiotic stress(es)?	⊠ Yes □ No	Comments: Idem as comment on Q9				
Q23. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q24. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes	Comments: <type here=""></type>				
Q25. Is there any other issue or concept that you would like to see included in this section of the Guidance?	⊠ Yes □ No	Comments: Idem as comment Q20				

Risk assessment of living modified mosquitoes						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q26. Does this section provide useful guidance when conducting risk assessments of LM mosquitoes in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q27. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM mosquitoes?	⊠ Yes □ No	Comments: Idem as comment Q9, however, given the complexity of mosquitos VM - due to is mobility - need to be further emphasized.				
Q28. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q29. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q30. Is there any other issue or concept that you would like to see included in this section of the Guidance?	⊠ Yes □ No	Comments: Idem as comment Q20				

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.

Q31. The Guidance proves to be very useful in setting the national guidance for risk assessment. The core principles included for risk assessment are useful to improve the national biosafety framework (this is the case of the Plurinational State of Bolivia, that used as reference the the section on "Overarching issues in the Risk Assessment Process" to strengthen its biosafety regulation).
